Parabilis Medicines Closes Upsized IPO, Raises $770.5M with Full Overallotment Exercise
PBLS is trading near its 52-week low of $26.61 (13% above the low).
Summary
Parabilis Medicines has closed its upsized initial public offering, raising $770.5 million in gross proceeds from the sale of 38,525,000 shares at $20.00 each. This includes the full exercise of the underwriters' overallotment option, indicating strong market demand. The company also secured an additional $75 million through a concurrent private placement to Regeneron Pharmaceuticals. This substantial capital infusion, following the IPO pricing yesterday, provides critical funding for the clinical-stage biopharmaceutical company's drug development pipeline.
At the time of this announcement, PBLS was trading at $30.00 on NASDAQ in the Life Sciences sector. The 52-week trading range was $26.61 to $34.47. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.